Abstract | BACKGROUND: OBJECTIVE: The aim of this multicenter placebo-controlled, double-blind study was to confirm the efficacy and safety of topically applied IFN in a large sample of patients. METHODS: After removal of CA by CO2 laser surgery, electrocautery or cryosurgery, 120 patients applied either recombinant IFN-beta (0.15 or 1.0 x 10(6) IU/g) or placebo gel to the affected areas 5 times daily for 4 weeks. The patients were followed for a total of 24 weeks or until recurrence of CA was observed, respectively. RESULTS: In the 105 patients evaluated for efficacy after 24 weeks, recurrence rates were 75% (27/36 patients) in the placebo group, 62% (21/34) in the 1.0 x 10(6) IU/g group (n.s.) and 54% (19/35) in the 0.15 x 10(6) IU/g group (p = 0.034). Only few mild adverse events were noted, which were almost limited to the application site. CONCLUSION: Topical application of gel containing 0.15 x 10(6) IU/g recombinant IFN-beta is safe and appears to reduce the recurrence of CA after surgical treatment.
|
Authors | G Gross, T Rogozinski, H Schöfer, S Jabłońska, A Roussaki, C Wöhr, J Brzoska |
Journal | Dermatology (Basel, Switzerland)
(Dermatology)
Vol. 196
Issue 3
Pg. 330-4
( 1998)
ISSN: 1018-8665 [Print] Switzerland |
PMID | 9621141
(Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)
|
Chemical References |
- Antiviral Agents
- Recombinant Proteins
- Interferon-beta
|
Topics |
- Administration, Cutaneous
- Adult
- Antiviral Agents
(therapeutic use)
- Chemotherapy, Adjuvant
- Condylomata Acuminata
(drug therapy, prevention & control)
- Double-Blind Method
- Female
- Humans
- Interferon-beta
(therapeutic use)
- Male
- Pilot Projects
- Recombinant Proteins
(therapeutic use)
- Recurrence
- Skin Diseases
(drug therapy, prevention & control)
- Treatment Outcome
|